DNA-In® CRISPR transfection reagent is optimized for large plasmid delivery of CRISPR/Cas9 vectors into a range of cell types. This reagent is especially well-suited for hard-to-transfect primary cells. Below, a Cas9-GFP plasmid was delivered into primary fibroblasts, muscles cells, keratinocytes and others primary cells and commonly used cell types with high efficiency and low toxicity.
 |  |  |
Human dermal primary fibroblasts (above) were plated to give ~70% plating density on the day of transfection. Cells were transfected with Cas9-GFP 24 hours after plating. Cells were labelled with anti-GFP (green) to observe low expression of Cas9-GFP vector and Hoechst 3342 (blue) to view nuclei. DNA-In® CRISPR transfected cells (left image) show significantly higher Cas9 transfection efficiency vs cells transfected with competitor reagents (L2K, L3K).
 |  |  |
Human primary keratinocytes (above) were plated to give a 50-70% plating density on the day of transfection. Cells were transfected with Cas9-GFP 24 hours after plating. Cells were labelled with anti-GFP (green) to observe low expression of Cas9-GFP vector and Hoechst 3342 (blue) to view nuclei. DNA-In® CRISPR transfected cells (left image) show significantly higher Cas9 transfection efficiency vs cells transfected with competitor reagents (L2K , L3K).
 |  |  |
C2C12 mouse myoblasts (above) were plated to give a 50-70% plating density on the day of transfection. Cells were transfected with Cas9-GFP 24 hours after plating. Cells were labelled with anti-GFP (green) to observe low expression of Cas9-GFP vector and Hoechst 3342 (blue) to view nuclei. DNA-In® CRISPR transfected cells (left image) show significantly higher Cas9 transfection efficiency vs cells transfected with competitor reagents (L2K, L3K).
 |  |  |
Human skeletal muscle cells (above) were plated to give a 50-70% plating density on the day of transfection. Cells were transfected with Cas9-GFP 24 hours after plating. Cells were labelled with anti-GFP (green) to observe low expression of Cas9-GFP vector and Hoechst 3342 (blue) to view nuclei. DNA-In® CRISPR transfected cells (left image) show significantly higher Cas9 transfection efficiency vs cells transfected with competitor reagents (L2K, L3K).
Optimized for large plasmid DNA containing Cas9/GFP/ guideRNA ( all-in-one).
High efficiency delivery of Cas9 expression vectors in hard-to-transfect primary cells.
DNA-In® is registered trademarks of Molecular Transfer, Inc.
Lipofectamine®, Opti-MEM® are registered trademarks of Thermo Fisher Scientific Inc.
技术支持：易动力网络
